Novel treatment strategies and key research priorities for patients with breast cancer and central nervous system (CNS) metastases

Despite improvements in surgical techniques, advances in delivery of radiation therapy, and development of therapies with central nervous system (CNS) activity, the presence of CNS metastases from breast cancer is frequently associated with a poor prognosis. In 2023, the leadership of the Breast International Group and National Cancer Institute's National Clinical Trials Network convened a CNS working group to identify key challenges and discuss ways that international collaborations could push forward progress in the field. This review reflects initial discussions of the working group and addresses (1) the possible role of screening for CNS metastases, (2) optimal sequencing of local and systemic therapies among patients with human epidermal growth factor receptor 2 (HER2)-positive CNS metastases, (3) management of leptomeningeal disease, and (4) the importance of developing innovative clinical trials for treatment and prevention of CNS metastases across breast cancer subtypes that is informed by preclinical data/basic science, with seamless knowledge translation to allow for rapid clinical adoption.

Authors

Institutions

Publication Details

Journal
npj Breast Cancer
Published
2025-12-20
DOI
https://doi.org/10.1038/s41523-025-00856-2
Primary Topic
Brain Metastases and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Novel treatment strategies and key research priorities for patients with breast cancer and central nervous system (CNS) metastases

Sarah Sammons, Priscilla Kaliopi Brastianos, N Lin, C. Palmieri et al.
npj Breast Cancer
Brain Metastases and Treatment
article

Novel treatment strategies and key research priorities for patients with breast cancer and central nervous system (CNS) metastases

Sarah Sammons, Priscilla Kaliopi Brastianos, N Lin, C. Palmieri, Razis Ed, Rupert A. Bartsch, M. Ahluwalia, CK Anders, Linderholm Be, Eva Schumacher-Wulf, Elisa Agostinetto, Elisabeth G. E. de Vries, Sarra El-Abed, Arjun Sahgal, Ciara C. O’Sullivan, Fatima Cardoso, Katarzyna J. Jerzak, Margaret E. Gatti-Mays
article en

Abstract

Despite improvements in surgical techniques, advances in delivery of radiation therapy, and development of therapies with central nervous system (CNS) activity, the presence of CNS metastases from breast cancer is frequently associated with a poor prognosis. In 2023, the leadership of the Breast International Group and National Cancer Institute's National Clinical Trials Network convened a CNS working group to identify key challenges and discuss ways that international collaborations could push forward progress in the field. This review reflects initial discussions of the working group and addresses (1) the possible role of screening for CNS metastases, (2) optimal sequencing of local and systemic therapies among patients with human epidermal growth factor receptor 2 (HER2)-positive CNS metastases, (3) management of leptomeningeal disease, and (4) the importance of developing innovative clinical trials for treatment and prevention of CNS metastases across breast cancer subtypes that is informed by preclinical data/basic science, with seamless knowledge translation to allow for rapid clinical adoption.

npj Breast CancerVol. 12(1)
Baptist Hospital of Miami (US), Université Libre de Bruxelles (BE), Sunnybrook Health Science Centre (CA), Mayo Clinic (US), University of North Carolina Health Care (US), University Medical Center Groningen (NL), University of Liverpool (GB), University of Groningen (NL), University of Toronto (CA), Breast Cancer Alliance (US), Sahlgrenska University Hospital (SE), Institut Jules Bordet (BE), Clatterbridge Cancer Centre NHS Foundation Trust (GB), Breast International Group (BE), Massachusetts General Hospital (US), Dana-Farber Cancer Institute (US), Hygeia Hospital (GR), Dana-Farber/Harvard Cancer Center (US), Centrum für Integrierte Onkologie (DE), Duke Cancer Institute, The Ohio State University (US), Medical University of Vienna (AT)
Breast Cancer Research Foundation
Openalex Percentile: Top 29%
Brain Metastases and Treatment
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.